Center for Cancer Immune Therapy, Denmark Report issue

Academic/Hospital Phase 1

Organization Overview

First Clinical Trial
2018
NCT03566446
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2018

Timeline

NOW
  • Now

Alternative names

Center for Cancer Immune Therapy, Denmark

Active Ingredients

Drugs in Phase 1 Trials (2)

calrlong36 (1 trial)

montanide isa51 (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Myeloproliferative Disorders (Phase 1)

Neoplasms (Phase 1)

Primary Myelofibrosis (Phase 1)

Thrombocythemia, Essential (Phase 1)

Thrombocytosis (Phase 1)

Overview

  • Highest Phase: Phase 1
  • # of Trials: 1
  • # of Trial APIs: 2